Overview of 8 HORAS

Property	Description
Active Ingredient	Eszopiclone
Form	Film-coated Tablet
Pharmacological Class	Non-benzodiazepine Hypnotic (Z-drug)
General Purpose	Management of difficulties with insomnia
Origin	Synthetic Compound

Defining 8 HORAS: Identity and Pharmacological Class

The medicinal preparation 8 HORAS contains the active substance Eszopiclone, which is structurally classified as a cyclopyrrolone derivative. It belongs to the broader category of sedative-hypnotics and is specifically identified as a Non-benzodiazepine hypnotic (Z-drug), a class recognized for its targeted effect on sleep regulation. As a synthetic compound, Eszopiclone is the pure active stereoisomer of zopiclone. Due to its potential for dependence, this substance is designated as a Schedule IV controlled substance, confirming its status as a regulated, prescription-only medication.

Composition and Physical Form of the Preparation

The functional core of the preparation is Eszopiclone, utilized as the single active ingredient for its intended pharmacological effect. This medication is manufactured as a film-coated tablet intended exclusively for oral administration. The physical formulation relies on carefully selected inactive ingredients, such as Hypromellose, which serves as an essential excipient to ensure the required structural integrity and predictable delivery of the active compound within the gastrointestinal tract.

General Purpose: Managing Difficulties with Insomnia

The general purpose of the 8 HORAS preparation is to support individuals experiencing challenges associated with chronic insomnia. The compound works by binding to the GABA-A receptor complexes in the brain, enhancing the activity of the inhibitory neurotransmitter, Gamma-aminobutyric acid (GABA). This specific interaction reduces neuronal excitability, helping to mitigate the challenges related to both the difficulty of falling asleep (sleep onset) and the issue of staying asleep (sleep maintenance) throughout the night. The active substance helps promote necessary sleep continuity.

Regulatory References

Eszopiclone: MedlinePlus Drug Information

What side effects are possible with 8 HORAS?

Possible Side Effects and Safety Information

The safety profile for 8 HORAS, which contains the active ingredient Eszopiclone, is formally documented by regulatory authorities (such as the FDA and EMA) through classification of adverse reactions and specific safety statements. The reported side effects are categorized based on their official frequency of occurrence in clinical data.

Officially Documented Adverse Reactions

Adverse reactions are grouped by the physiological system affected and their reported frequency:

Category	Common Effects (ge 1/100 to < 1/10)
Nervous System	Dysgeusia (unpleasant taste), Headache, Somnolence, Dizziness
Gastrointestinal	Dry mouth, Nausea
Psychiatric	Anxiety, Hallucinations, Abnormal dreams

The most frequently cited adverse event is the development of an unpleasant or metallic taste (Dysgeusia). Less common effects may include confusion, reduced libido, and amnesia.

Serious Adverse Reactions and Safety Constraints

The regulatory labeling highlights specific reactions that are clinically serious, regardless of their low frequency. These include Complex Sleep-Related Behaviors such as sleep-driving, preparing food, or making phone calls while not fully awake, which can result in serious harm and are subject to mandatory warnings.

Furthermore, the medicine is officially designated as a Schedule IV controlled substance due to its established potential for dependence and abuse, a risk that increases with the duration of use. Safety considerations also exist for specific populations; older adults are noted to have a heightened risk for dizziness and impaired coordination, potentially leading to falls. Risks tied to exposure include next-day impairment (reduced alertness and coordination) and the possibility of rebound insomnia following abrupt discontinuation of treatment.

Overdose and Emergency Response

Overdose Manifestations and Severity

Overdose with the active substance in 8 HORAS is characterized by an exaggeration of its CNS depressant effects, as documented in official regulatory labeling. Clinical manifestations range from increased somnolence (excessive drowsiness) to the loss of consciousness, described as coma. Severe or life-threatening scenarios may involve respiratory depression and hypotension. A fatal outcome has been reported, particularly when the substance is consumed alongside alcohol or other central nervous system depressants. Regulatory documents advise prescribing the least number of tablets feasible to mitigate the risk of intentional overdose.

Required Emergency Actions and Supportive Care

Regulatory bodies explicitly mandate seeking immediate medical attention if an overdose is suspected. Urgent help, including contacting emergency services, is required if the patient exhibits severe clinical signs such as difficulty breathing, collapse, or the inability to be awakened.

The procedural approach described in prescribing information focuses on general symptomatic and supportive measures. Treatment includes close monitoring of vital functions, such as respiration and blood pressure. The antagonist Flumazenil is stated as an agent that may be useful in management. Caution is noted for elderly patients and individuals with severe hepatic impairment due to factors that may amplify toxicity.

Therapeutic Uses of 8 HORAS

8 HORAS: Main Uses and Benefits

Quick Facts: Primary Therapeutic Domains
Indicated for: Temporary relief of minor pain
Addresses: Minor pain of arthritis, muscular aches, backache
Supports: Reduction of minor aches associated with headaches and the common cold

8 HORAS is a medication indicated for the temporary management and relief of various minor aches and pains. Its primary therapeutic domains include supporting the reduction of discomfort associated with minor pain of arthritis and muscle aches. It is also used to provide relief from backache, premenstrual and menstrual cramps, toothache, and discomfort related to the common cold.

This medication is available over-the-counter and is designed to address pain that is generally considered mild to moderate in intensity. Its use is appropriate for addressing symptoms that may interfere with daily activities. As with any pain relief medication, its use is intended for temporary symptom management. Patients should consult a healthcare provider for any persistent or severe pain conditions.

Eligibility and Restrictions for Use

Who Can and Cannot Use 8 HORAS (Eszopiclone)?

Contraindicated Populations The medicine is strictly contraindicated for patients with a known hypersensitivity to Eszopiclone or any component of the formulation. Use is also prohibited for individuals who have previously experienced complex sleep behaviors (such as sleep-driving or sleepwalking) after taking this or any other sedative-hypnotic agent.

Age-Group Eligibility This medication is approved for use in adults (18 years and older). Its safety and effectiveness are not established in children and adolescents under 18, and its use is therefore not recommended in this population. Older adults (ge65 years) are eligible, but the total daily dose is strictly limited by regulators to 2 mg due to increased next-day impairment risk.

Conditional Use and Restrictions Patients with severe hepatic impairment must also restrict their total daily dose to a maximum of 2 mg, as drug exposure is significantly increased in this population. Caution is advised for patients with pre-existing depression or a history of alcohol or substance abuse due to heightened risks. Use during pregnancy and lactation requires specific caution, permitted only when the benefit is deemed to outweigh the potential risk.

What should I know about interactions with other medicines?

The interaction profile for 8 HORAS (Eszopiclone) is defined by documented pharmacokinetic and pharmacodynamic constraints, establishing necessary restrictions and timing requirements.

Metabolic and Exposure Interactions

Co-administration with potent CYP3A4 inhibitors (such as Ketoconazole or Itraconazole) results in a 2.2-fold increase in eszopiclone exposure (AUC) due to inhibition of the enzyme’s primary metabolic pathway. Because of this risk of elevated exposure, this combination is formally contraindicated in elderly patients (aged 65 or older). Conversely, potent CYP3A4 inducers (e.g., Rifampicin) are expected to decrease eszopiclone exposure and may reduce its effect. A specific population risk is noted in official labeling: exposure is increased 2-fold in patients with severe hepatic impairment.

Pharmacodynamic and Administrative Constraints

Co-administration with alcohol (ethanol) or other CNS depressants (including opioids, benzodiazepines, and antipsychotics) results in additive pharmacodynamic effects such as enhanced sedation and psychomotor impairment, necessitating avoidance. Taking the medicine with or immediately after a heavy, high-fat meal delays absorption and reduces the drug’s mean maximum concentration ( C max), officially reducing its intended effect on sleep onset. Co-administration with Olanzapine resulted in a specific pharmacodynamic interaction on psychomotor function, despite no pharmacokinetic changes.

Mechanism of Action

8 HORAS, a nitrogen-containing bisphosphonate, acts through a highly selective mechanism localized primarily to the bone matrix. Due to its high affinity for calcium, the compound rapidly binds to hydroxyapatite crystals at sites of active bone remodeling and is subsequently internalized by active osteoclasts during the bone resorption process.

Once inside the osteoclast, 8 HORAS functions as an inhibitor of the enzyme farnesyl pyrophosphate (FPP) synthase, a key component of the mevalonate pathway. Inhibition of FPP synthase prevents the necessary post-translational modification, known as prenylation, of specific small GTP-binding proteins (e.g., Rho, Rac, Rab).

Since prenylation is essential for the proper membrane localization, cytoskeletal organization, and function of osteoclasts, this molecular cascade ultimately disrupts the cell's ability to form the ruffled border and secure attachment required for bone resorption. The inhibited function and subsequent reduced viability of osteoclasts leads to a decrease in bone turnover and suppression of osteoclast-mediated bone resorption, modulating the balance between bone formation and breakdown.

Dosage and Administration Information

Administration Scope

Instruction	Detail
Route of administration	Oral via film-coated tablet in 1 mg, 2 mg, or 3 mg strengths.
Dosing schedule	The recommended starting dose is 1 mg once daily immediately before bedtime. The total dose should not exceed 3 mg per day.
Timing in relation to meals (if applicable)	The medication should not be taken with or immediately following a heavy, high-fat meal, as this administration condition slows absorption and reduces the drug's effect on sleep onset.
Preparation requirements (if applicable)	The film-coated tablet must be swallowed whole and should not be broken, crushed, or chewed.
Age-group administration rules	The maximum total dose for older adults (geriatric) or debilitated patients should not exceed 2 mg once daily.
Missed-dose rules	Because of the required timing, if a dose is missed, it should be skipped and the normal schedule resumed on the next night when sleep is needed.
Special procedural conditions	The medicine must be taken only when the user can commit to a minimum of 7 to 8 hours remaining before the planned time of awakening.

Resulting Procedural Structure

Official step sequence:

Take the required dose once daily immediately prior to getting into bed.
Swallow the tablet whole without modification.
Avoid taking the dose with heavy, high-fat food to preserve the intended onset time.

Connection to the overall use protocol (2–4 sentences)

The official instructions establish a highly time-constrained administration protocol, mandating a single oral dose only when a full night of sleep is guaranteed and placing constraints on concurrent food intake. This structure standardizes use across populations by setting specific dose maximums based on age and hepatic function. The protocol emphasizes short-term use, requiring a formal reassessment if the stated usage goal is not met within 7 to 10 days of starting administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for 8 HORAS

Evidence for Use in Chronic Insomnia in Adults

The research base for 8 HORAS (Eszopiclone) in the context of chronic insomnia is primarily based on Randomized Controlled Trials (RCTs). This type of research design is considered important for evaluating how symptoms change over time. In these trials, adult participants with established, long-term sleep difficulty were given either the study medication or an inactive substance (placebo), and their sleep patterns were measured. Research in these RCTs utilized both objective sleep parameters (measured in a lab setting) and patient-reported outcomes describing perceived discomfort and experience.

Studies focused on key outcomes related to difficulties falling asleep and staying asleep. Studies were designed to observe differences in measured outcomes like sleep onset latency (time to fall asleep) and wake time after sleep onset between the groups receiving the study medication and those receiving placebo. Research also monitored outcomes reflecting daily functioning, such as next-day alertness, to determine the patterns of reported functioning during the day.

Long-Term Studies and Follow-Up Duration

Studies exploring the use of 8 HORAS were conducted across different time intervals, including short-term and intermediate-term (up to 3 months). Furthermore, the regulatory evidence base includes research observing responses over defined time intervals lasting up to six months in controlled settings. These longer studies were designed to track outcomes over continuous use. After the controlled six-month period, some research followed patients in open-label extension studies for up to 12 months. This extended evidence contributes to the understanding of patient-reported experience over longer use.

However, the highest level of research certainty, derived from the strictly controlled, double-blind study design, is primarily associated with the six-month duration. Long-term effects are not fully established beyond one year, as the data are still emerging and research is ongoing in these extended timeframes.

What is Still Uncertain About the Research Landscape

It is important to understand the limitations that exist in the body of evidence. Comparative evidence is lacking regarding direct head-to-head comparisons of 8 HORAS against established non-pharmacological treatments, such as Cognitive Behavioral Therapy for Insomnia (CBT-I), or against other sedative-hypnotics. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. Sample sizes were modest in some special population studies, meaning that research provides limited insight into how these groups will respond outside of highly controlled settings.

Frequently Asked Questions (FAQ)

Common questions about 8 HORAS (FAQ)

Q: Why do some health forums mention that 8 HORAS should be taken at a specific time of day?

Official instructions state the dose must be taken immediately before bedtime and only when you can commit to a minimum of 7 to 8 hours of sleep remaining. This timing constraint is officially stated to manage the potential risk of next-day impairment, which includes reduced alertness or coordination.

Q: How quickly is 8 HORAS expected to start working after the first use?

Studies show the medication is rapidly absorbed after being swallowed. Peak concentration of the active substance in the body is typically achieved within approximately one hour after oral administration.

Q: Are there any common foods or drinks that should be avoided while taking 8 HORAS?

Official instructions note that the medication should be avoided with or immediately following a heavy, high-fat meal because this administration condition can delay absorption and reduce the intended effect on sleep onset. Co-administration with alcohol is also specifically advised against due to the risk of enhanced sedation.

Q: How long does the effect of 8 HORAS typically last in the body?

Official pharmacokinetic studies indicate that the drug is eliminated from the body with a mean half-life (t1/2) of approximately 6 hours in healthy adults. This half-life describes the time it takes for the amount of medication in the body to decrease by half.

Q: What is the official definition of the condition 8 HORAS is approved to treat?

According to regulatory documents, the medication is indicated for the treatment of insomnia, defined in clinical trials by difficulties with both sleep latency (falling asleep) and sleep maintenance (staying asleep).

Q: Does 8 HORAS affect the ability to drive or operate machinery?

Official labeling includes a mandatory warning that patients must be cautioned against driving or engaging in other hazardous activities requiring complete mental alertness the day after use. The risk of next-day impairment is associated with the dose used.

Q: Is 8 HORAS considered a short-term or long-term medication?

The medication is approved for the treatment of insomnia, and controlled clinical trials have supported its effectiveness for up to six months of continuous use. The official protocol requires a reassessment if the stated usage goal is not met within 7 to 10 days of starting administration to evaluate for a possible underlying cause of the sleep difficulty.

Q: What happens if a person stops using 8 HORAS suddenly?

Abrupt discontinuation may result in rebound insomnia, a temporary difficulty in sleeping that is worse than before treatment. Official warnings also note that stopping suddenly can be associated with withdrawal side effects such as anxiety, nausea, or abnormal dreams.

Q: How do official documents describe the possible mood-related side effects of 8 HORAS?

Official documentation lists anxiety and abnormal dreams as common effects. Serious side effects that may occur can include changes in abnormal thinking or behavior, worsening depression, agitation, confusion, and hallucinations.

Q: Does 8 HORAS interact with common antidepressants or anxiety medications?

The medication may have additive effects when co-administered with other CNS depressants (medicines that slow down the brain), which includes certain antidepressants and anxiety medications. This can increase the risk of enhanced sedation, dizziness, and difficulty concentrating.

Q: Are there any known interactions between 8 HORAS and herbal supplements?

Interactions are noted with substances that affect the central nervous system (CNS). This includes certain supplements or products containing caffeine, due to the potential for either reduced effectiveness of 8 HORAS or enhanced sedative effects.

Q: Can 8 HORAS be used by people who are 65 years old or older?

Older adults are eligible for use, but official regulatory labeling specifies a strict daily maximum dose for this population. This dose limitation is due to a heightened risk for dizziness, impaired coordination, and next-day impairment in this age group.

Q: Can 8 HORAS be taken if someone has a pre-existing liver condition?

Official regulatory information specifies a strict dose limitation for patients with severe hepatic impairment (severe liver problems). This restriction is in place because drug exposure is significantly increased in this patient population, which can affect the medication's effects.

Q: What if a user is allergic to an inactive ingredient in 8 HORAS?

Official contraindications state that the medicine is officially prohibited for patients with a known hypersensitivity (allergic reaction) to the active substance or any component of the formulation, which includes inactive ingredients.

Q: What is the chemical name or active ingredient in 8 HORAS?

The active substance in the preparation is Eszopiclone. The formal chemical identity is described in regulatory documents as (+)-(5S)-6-(5-chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b] pyrazin-5-yl 4-methylpiperazine-1-carboxylate.

Q: Is 8 HORAS approved for use in children under the age of 12?

Official labeling states that the safety and effectiveness of the medication have not been established in children and adolescents under 18 years of age. Its use is therefore not recommended for any patient in this age group.

Q: Is 8 HORAS available as a generic medicine?

Yes, the active ingredient Eszopiclone is approved by the FDA as a generic version of the brand name product.

Q: What is the difference between the main ingredient in 8 HORAS and its metabolites?

After the drug is taken, the body metabolizes it into primary compounds, known as metabolites. Regulatory documents identify these primary metabolites, noting that they bind to the brain's GABA receptors with substantially lower potency than the main active ingredient itself.

Q: Is the medication designed to treat symptoms or the underlying cause of the condition?

The drug is indicated for the treatment of insomnia symptoms (difficulty falling asleep and staying asleep). Official documentation states that if sleep problems persist, the patient should be reevaluated to determine if an underlying medical diagnosis may be causing the sleep difficulty.

How should 8 HORAS be stored and disposed of?

How to Store and Dispose of 8 HORAS (Acetaminophen Extended-Release)

8 HORAS must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The packaging allows for brief temperature excursions between 15 C and 30 C.

The product must be protected from excessive moisture and should be kept in its original container at all times to maintain stability. For safety, it is a strict requirement to keep the medication out of reach of children.

For disposal, any unused or expired medication must be discarded in accordance with local requirements. Official guidance advises against disposing of the tablets by flushing them down a toilet or pouring them down a drain.

8 HORAS